AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
Rhea-AI Summary
AtaiBeckley (NASDAQ: ATAI) appointed Michael Faerm as Chief Financial Officer effective March 9, 2026. Faerm brings more than 25 years of finance, equity research and banking experience and will lead financial strategy, capital markets and operations. Anne Johnson will transition to Chief Accounting Officer to preserve continuity. The company noted BPL-003 is advancing toward Phase 3 as its clinical programs progress.
AI-generated analysis. Not financial advice.
Positive
- New CFO effective March 9, 2026
- 25+ years of finance and life-sciences experience
- Anne Johnson shifts to Chief Accounting Officer for continuity
- BPL-003 advancing toward Phase 3
Negative
- Near-term finance leadership transition during late-stage development
News Market Reaction – ATAI
On the day this news was published, ATAI declined 3.29%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.9% during that session. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $50M from the company's valuation, bringing the market cap to $1.46B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ATAI was up 3.95% with elevated volume, while momentum peers like QURE and ABUS gained 3.33% and
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Investor conferences | Positive | +6.4% | Announced CEO and IR participation in multiple March 2026 investor conferences. |
| Jan 16 | Clinical data update | Positive | -1.9% | Reported positive Phase 2b BPL-003 data and supportive preclinical findings at ACNP. |
| Jan 08 | 2026 outlook | Positive | -0.8% | Provided 2026 clinical outlook, Phase 3 guidance for BPL-003, and funding into 2029. |
| Dec 30 | Redomiciliation | Positive | +2.8% | Completed redomiciliation to Delaware with one-for-one share exchange and cost benefits. |
| Dec 23 | Index inclusion | Positive | +0.7% | Announced inclusion in the Nasdaq Biotechnology Index and ~$300M capital raised in 2025. |
Recent news has generally been positive and the stock more often reacted with modest gains, though key clinical updates have occasionally seen short-term selling pressure.
Over the past few months, AtaiBeckley has executed several strategic steps, including addition to the Nasdaq Biotechnology Index, completion of its U.S. redomiciliation on Dec 30, 2025, and a 2026 outlook highlighting positive Phase 2b data for BPL-003 and a pipeline of upcoming readouts. Conference participation and investor outreach preceded a 6.44% gain on Feb 17, 2026. Today’s CFO appointment fits into this pattern of building late-stage readiness and capital markets infrastructure.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registered on September 29, 2025, allowing registered offerings and resales. It has been used in at least 3 prospectus supplements, including a resale registration tied to the Beckley Psytech acquisition, and remains effective through 2028-09-29.
Market Pulse Summary
This announcement adds an experienced capital markets executive as CFO just as BPL-003 advances toward Phase 3 and a broader clinical pipeline moves forward. It follows index inclusion, U.S. redomiciliation, and substantial 2025 fundraising of about $300 million. Investors may track how the new CFO manages cash of $30.4 million, securities of $84.2 million, and the existing shelf to support late-stage development without undue shareholder pressure.
Key Terms
PIPE financing financial
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026.
Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company’s financial strategy, capital markets activities, and overall financial operations.
Anne Johnson, who has served as Chief Financial Officer since 2024, will transition to the role of Chief Accounting Officer upon the effective date of Mr. Faerm’s appointment. In this position, she will continue to lead accounting and financial operations, working closely with Mr. Faerm to ensure continuity and operational consistency.
“We are delighted to welcome Mike Faerm to AtaiBeckley as our Chief Financial Officer,” said Srinivas Rao, Chief Executive Officer and Co-Founder of Atai Beckley. “Mike brings deep strategic finance experience and a strong understanding of the life sciences sector, which will be important as BPL-003 moves toward Phase 3 and our broader clinical-stage programs continue to advance.”
“We also appreciate Anne’s continued leadership as Chief Accounting Officer. Her operational expertise and familiarity with our financial systems provide important continuity. Together, Mike and Anne create a strong and complementary finance leadership structure for the Company.”
“I’m excited to join AtaiBeckley at this important stage,” said Mr. Faerm. “With BPL-003 advancing toward Phase 3 and a strong clinical-stage pipeline supporting the broader strategy, this is a compelling time to help shape the Company’s financial and capital markets approach. I look forward to leading our financial strategy, partnering with Anne in her role as Chief Accounting Officer, and working closely with the full leadership team to support disciplined execution as the Company moves into late-stage development.”
Mr. Faerm most recently served as Chief Financial Officer at Viracta Therapeutics, Inc. Previously, he was Interim Chief Financial Officer at Harpoon Therapeutics, Inc., which was acquired by Merck, and where he helped lead a
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: statements regarding our executive transition; our business strategy and plans; and the timing of development and progress of trials of our product candidates, including BPL-003.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in AtaiBeckley’s other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Investor and Media Relations:
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com
Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com
